Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Mapping antibody escape in SARS-CoV-2: Several antibodies are in use or under development as therapies to treat COVID-19. As new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge, it is important to predict whether they will remain susceptible to antibody treatment. Starr et al. used a yeast library that covers all mutations to the SARS-CoV-2 receptor-binding domain that do not strongly disrupt binding to the host receptor (ACE2) and mapped how these mutations affect binding to three leading anti–SARS-CoV-2 antibodies. The maps identify mutations that escape antibody binding, including a single mutation that escapes both antibodies in the Regeneron antibody cocktail. Many of the mutations that escape single antibodies are circulating in the human population. Science , this issue p. 850
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Escape maps are consistent with viral mutations selected in cell culture and a persistently infected patient. (A) Viral escape mutations selected by Regeneron with spike-pseudotyped VSV in cell culture in the presence of antibody (12). (B) Escape maps like those in Fig. 1A, but showing only mutations accessible by single-nucleotide changes to the Wuhan-Hu-1 sequence, with nongray colors indicating mutations in cell culture (red), the infected patient (blue), or both (purple). Figure S5 shows these maps colored by how mutations affect ACE2 affinity or RBD expression. (C) Dynamics of RBD mutations in a patient treated with REGN-COV2 at day 145 of infection (black dot-dash vertical line). E484A rose in frequency in linkage with F486I, but because E484A is not an escape mutation in our maps, it is not shown in other panels. See also fig. S4. (D) The escape mutations that arise in cell culture and the infected patient are single-nucleotide–accessible and escape antibody binding without imposing a large cost on ACE2 affinity [as measured using yeast display (7)]. Each point is a mutation, with shape and color indicating whether it is accessible and selected during viral growth. Points farther to the right on the x axis indicate stronger escape from antibody binding; points higher up on the y axis indicate higher ACE2 affinity.](https://figures.cochat.ai/paper-figures/91cf075ab18741e0a80bfb01ad2b708a/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-2.jpg)

![Fig. 4 Structural context of escape mutations. (A) Escape maps projected on antibody-bound RBD structures. [REGN10933 and REGN10987: Protein Data Bank (PDB) ID 6XDG (11); LY-CoV016: PDB ID 7C01 (13)]. Antibody heavy- and light-chain variable domains are shown as blue cartoons, and the RBD surface is colored to indicate how strongly mutations at that site mediate escape (white indicates no escape, red indicates strongest escape site for that antibody or cocktail). Sites where no mutations are functionally tolerated are colored gray. (B) For each antibody, sites were classified as direct antibody contacts (non-hydrogen atoms within 4 Å of antibody), antibody-proximal (4 to 8 Å), or antibody-distal (>8 Å). Each point indicates a site, classified as escape (red) or non-escape (black). The dashed gray line indicates the cutoff used to classify sites as escape or non-escape (see materials and methods for details). Red and black numbers indicate how many sites in each category are escape or non-escape sites, respectively. Interactive visualizations are at https://jbloomlab.github.io/SARS-CoV-2-RBD_MAP_clinical_Abs/, and hypothesized mechanisms of escape and additional structural details for labeled points are shown in fig. S6.](https://figures.cochat.ai/paper-figures/854cbba408614d74b93381682c26dd9e/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several of the RBD mutations directly affect angiotensin-converting enzyme 2 (ACE2) receptor-binding affinity, which may affect infectivity, viral load, or transmissibility.11, 12, 13, 14”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations found in emergent S variants decrease sensitivity to neutralization by mAbs, convalescent plasma, and sera from vaccinated individuals (27, 37, 58, 61–70).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The B.1.1.7, B.1.351, and P.1 lineages all harbor a N501Y mutation in the RBD, which increases the affinity for the ACE2 receptor (57, 58), and a D614G mutation, which increases virion spike density, infectivity, and transmissibility (59, 60).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We tested four clinically approved monoclonal antibodies that target the RBD 18,19 (bamlanivimab (LY-CoV555), etesevimab (LY-CoV016), casirivimab (REGN10933) and imdevimab (REGN10987))”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
fastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
Li, H. (2013) · DROPS (Schloss Dagstuhl – Leibniz Center for Informatics) · doi:10.48550/arxiv.1303.3997 · Cited by 5,159
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEM
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 4,932
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Snakemake—a scalable bioinformatics workflow engine
Köster, J., & Rahmann, S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts480 · Cited by 2,780
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Research works printed but not linked: 2
- 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
- Regeneron Pharmaceuticals Inc. “Regeneron’s casirivimab and imdevimab antibody cocktail for COVID-19 is first combination therapy to receive FDA emergency use authorization ” press release (21 November 2020); https://investor.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive/.
Cited by
Items 201–300 of 750
Yang, W.-T., Huang, W.-H., Liao, T.-L., Hsiao, T.-H., Chuang, H.-N., & Liu, P.-Y. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s344099 · Cited by 53
Evolution of resistance to COVID-19 vaccination with dynamic social distancing
Lobinska, G., Pauzner, A., Traulsen, A., Pilpel, Y., & Nowak, M. A. (2022) · Nature Human Behaviour · doi:10.1038/s41562-021-01281-8 · Cited by 54
The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?
Guo, S., Liu, K., & Zheng, J. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59137 · Cited by 54
Intranasal gene therapy to prevent infection by SARS-CoV-2 variants
Sims, J. J., Greig, J. A., Michalson, K. T., Lian, S., Martino, R. A., Meggersee, R., Turner, K. B., Nambiar, K., Dyer, C., Hinderer, C. J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009544 · Cited by 48
Qin, S., Cui, M., Sun, S., Zhou, J., Du, Z., Cui, Y., & Fan, H. (2021) · Zoonoses · doi:10.15212/zoonoses-2021-0024 · Cited by 48
A biophysical model of viral escape from polyclonal antibodies
Yu, T. C., Thornton, Z., Hannon, W. W., DeWitt, W. S., Radford, C. E., Matsen, F. A., IV, & Bloom, J. D. (2022) · Virus Evolution · doi:10.1093/ve/veac110 · Cited by 46
Self-citationSARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Iketani, S., & Ho, D. D. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.03.008 · Cited by 51
Lassaunière, R., Fonager, J., Rasmussen, M., Frische, A., Polacek, C., Rasmussen, T. B., Lohse, L., Belsham, G. J., Underwood, A., Winckelmann, A. A., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.698944 · Cited by 46
Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview
Mehra, R., & Kepp, K. P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00433 · Cited by 45
Spike protein of SARS-CoV-2 variants: a brief review and practical implications
Candido, K. L., Eich, C. R., de Fariña, L. O., Kadowaki, M. K., Silva, J. L. D. C., Maller, A., & Simão, R. D. C. G. (2022) · Brazilian Journal of Microbiology · doi:10.1007/s42770-022-00743-z · Cited by 50
Mutational analysis of structural proteins of SARS-CoV-2
Jakhmola, S., Indari, O., Kashyap, D., Varshney, N., Das, A., Manivannan, E., & Jha, H. C. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06572 · Cited by 49
A highly potent antibody effective against SARS-CoV-2 variants of concern
Fenwick, C. W., Turelli, P., Perez, L. H., Pellaton, C., Esteves-Leuenberger, L., Farina, A., Campos, J., Lana, E., Fiscalini, F., Raclot, C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109814 · Cited by 52
“It was recently demonstrated that the neutralizing activity of these three mAbs could be negatively affected by mutation identified in circulating variants that are not affecting ACE2 binding to the open RBD (Starr et al., 2021) (Figure 5D).”
The Development of SARS-CoV-2 Variants: The Gene Makes the Disease
Pérez-Gómez, R. (2021) · Journal of Developmental Biology · doi:10.3390/jdb9040058 · Cited by 47
Engineering ACE2 decoy receptors to combat viral escapability
Arimori, T., Ikemura, N., Okamoto, T., Takagi, J., Standley, D. M., & Hoshino, A. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.06.011 · Cited by 45
Focosi, D., McConnell, S. A., & Casadevall, A. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100882 · Cited by 49
The evolutionary and functional significance of germline immunoglobulin gene variation
Pennell, M., Rodriguez, O. L., Watson, C. T., & Greiff, V. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.11.001 · Cited by 48
Ward, T., & Johnsen, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257978 · Cited by 49
Artificial intelligence for COVID-19: battling the pandemic with computational intelligence
Xu, Z., Su, C., Xiao, Y., & Wang, F. (2021) · Intelligent Medicine · doi:10.1016/j.imed.2021.09.001 · Cited by 53
“(3) Several mutations of COVID-19 are more transmissible [33] .”
ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2
Iwanaga, N., Cooper, L. M., Rong, L., Maness, N. J., Beddingfield, B. J., Qin, Z., Crabtree, J. M., Tripp, R. A., Yang, H., Blair, R. V., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103670 · Cited by 49
Burnett, D. L., Jackson, K., Langley, D. B., Aggarwal, A., Stella, A. O., Johansen, M. D., Balachandran, H., Lenthall, H., Rouet, R., Walker, G. J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.019 · Cited by 46
Chakraborty, C., Bhattacharya, M., & Sharma, A. R. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.006 · Cited by 46
Engdahl, T. B., Binshtein, E., Brocato, R. L., Kuzmina, N. A., Principe, L. M., Kwilas, S. A., Kim, R. K., Chapman, N. S., Porter, M. S., Guardado‐Calvo, P., et al. (2023) · eLife · doi:10.7554/elife.81743 · Cited by 46
SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants
Hattab, D., Amer, M. F. A., Al‐Alami, Z. M., & Bakhtiar, A. (2024) · Infection · doi:10.1007/s15010-024-02223-y · Cited by 51
“The resistance of etesevimab is likely associated with the presence of the K417N mutation (Table 3) [103].”
BackgroundHost barriers to SARS-CoV-2 demonstrated by ferrets in a high-exposure domestic setting
Sawatzki, K., Hill, N. J., Puryear, W. B., Foss, A. D., Stone, J. J., & Runstadler, J. A. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025601118 · Cited by 43
Guenthoer, J., Lilly, M., Starr, T. N., Dadonaite, B., Lovendahl, K. N., Croft, J. T., Stoddard, C. I., Chohan, V., Ding, S., Ruiz, F., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220948120 · Cited by 42
Self-citationACE2-lentiviral transduction enables mouse SARS-CoV-2 infection and mapping of receptor interactions
Rawle, D. J., Le, T. T., Dumenil, T. D., Yan, K., Tang, B., Nguyen, W., Watterson, D., Modhiran, N., Hobson‐Peters, J., Bishop, C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009723 · Cited by 44
Ferrari, M., Mekkaoui, L., Ilca, F. T., Akbar, Z., Bughda, R., Lamb, K., Ward, K., Parekh, F., Karattil, R., Allen, C. G., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00685-21 · Cited by 38
A phenomics approach for antiviral drug discovery
Rietdijk, J., Tampere, M., Pettke, A., Georgieva, P., Lapins, M., Berglund, U. W., Spjuth, O., Puumalainen, M.-R., & Puigvert, J. C. (2021) · BMC Biology · doi:10.1186/s12915-021-01086-1 · Cited by 44
Triveri, A., Serapian, S. A., Marchetti, F., Doria, F., Pavoni, S., Cinquini, F., Moroni, E., Rasola, A., Frigerio, F., & Colombo, G. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00857 · Cited by 41
IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2
Hale, M. R., Netland, J., Chen, Y., Thouvenel, C. D., Smith, K. N., Rich, L. M., Vanderwall, E. R., Miranda, M. C., Eggenberger, J., Hao, L., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220849 · Cited by 49
Ryu, D.-K., Kang, B., Noh, H., Woo, S., Lee, M., Nuijten, P. M., Kim, J., Seo, J.-M., Kim, C.-M., Kim, M., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.023 · Cited by 44
“The Delta has L452R, T478K and P681R in the spike protein (Table 1) which may contribute to increased infectivity, pathogenicity and immune evasion, resulting in re-infection or resistance to vaccine-elicited antibody and therapeutic antibodies [9,10].”
Focosi, D., McConnell, S. A., Sullivan, D. J., & Casadevall, A. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100991 · Cited by 42
Multiplexed assays of variant effect for clinical variant interpretation
McEwen, A. E., Tejura, M., Fayer, S., Starita, L. M., & Fowler, D. M. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-025-00870-x · Cited by 60
“Additionally, the authors repeated the RBD MAVEs in the presence of antibodies from multiple sources and identified spike RBD mutations that abrogated binding and rendered the therapeutic antibodies ineffective 167–169 .”
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
López, E., Haycroft, E. R., Adair, A., Mordant, F. L., O’Neill, M. T., Pymm, P., Redmond, S. J., Lee, W. S., Gherardin, N. A., Wheatley, A. K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150012 · Cited by 41
Ahmad, J., Jiang, J., Boyd, L. F., Zeher, A., Huang, R. K., Xia, D., Natarajan, K., & Margulies, D. H. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101202 · Cited by 40
Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance
Arora, P., Kempf, A. M., Nehlmeier, I., Graichen, L., Sidarovich, A., Winkler, M. S., Schulz, S. R., Jäck, H., Stankov, M. V., Behrens, G. M. N., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00772-y · Cited by 42
Kemp, F., Proverbio, D., Aalto, A., Mombaerts, L., d’Hérouël, A. F., Husch, A., Ley, C., Gonçalves, J. M., Skupin, A., & Magni, S. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110874 · Cited by 49
Changrob, S., Fu, Y., Guthmiller, J. J., Halfmann, P., Li, L., Stamper, C. T., Dugan, H. L., Accola, M., Rehrauer, W., Zheng, N.-Y., et al. (2021) · mBio · doi:10.1128/mbio.02975-21 · Cited by 41
Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein
Tan, Z. W., Tee, W.-V., Samsudin, F., Guarnera, E., Bond, P. J., & Berezovsky, I. N. (2022) · Structure · doi:10.1016/j.str.2021.12.011 · Cited by 38
Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 36
Gopinath, S., Ishak, A., Dhawan, N., Poudel, S., Shrestha, P. S., Singh, P., Xie, E., Tahir, P., Marzaban, S., Michel, J., et al. (2022) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed7050081 · Cited by 63
Baral, P. K., Yin, J., & James, M. N. G. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.07.013 · Cited by 37
Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic
González-Vázquez, L. D., & Arenas, M. (2023) · Genes · doi:10.3390/genes14020407 · Cited by 51
Using big sequencing data to identify chronic SARS-Coronavirus-2 infections
Harari, S., Miller, D., Fleishon, S., Burstein, D., & Stern, A. (2024) · Nature Communications · doi:10.1038/s41467-024-44803-4 · Cited by 40
Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease
Flynn, J. M., Huang, Q. Y. J., Zvornicanin, S. N., Schneider-Nachum, G., Shaqra, A. M., Yılmaz, N. K., Moquin, S. A., Dovala, D., Schiffer, C. A., & Bolon, D. N. A. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00125 · Cited by 37
Simulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens
Nuqui, X., Casalino, L., Zhou, L., Shehata, M., Wang, A., Tse, A. L., Ojha, A. A., Kearns, F. L., Rosenfeld, M. A., Miller, E. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50976-9 · Cited by 35
“On the other hand, due to selective immune pressure 16,17 , most of the mutations across different CoV strains and SARS-CoV-2 VOCs occur in S1 2,18 – 20 .”
BackgroundLusvarghi, S., Wang, W., Herrup, R., Neerukonda, S. N., Vassell, R. A., Bentley, L., Eakin, A. E., Erlandson, K. J., & Weiss, C. D. (2021) · Journal of Virology · doi:10.1128/jvi.01110-21 · Cited by 37
“Consistent with many reports (38, 52-60), the E484K substitution present in many lineages had a major impact on many nAbs, leading to a loss of potency for five nAbs (nAbs.”
ResultYin, V. C., Lai, S., Caniels, T. G., Brouwer, P. J. M., Brinkkemper, M., Aldon, Y., Liu, H., Yuan, M., Wilson, I. A., Sanders, R. W., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00804 · Cited by 36
Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts
Ko, K. K. K., Yingtaweesittikul, H., Tan, T. T., Wijaya, L., Cao, D. Y., Goh, S. S., Rahman, N. B. A., Chan, K. X. L., Tay, H. M., Sim, J. H. C., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00791-22 · Cited by 42
Martin, D. P., Weaver, S., Tegally, H., San, E. J., Shank, S. D., Wilkinson, E., Lucaci, A. G., Giandhari, J., Naidoo, S., Pillay, Y., et al. (2021) · PubMed · doi:10.34944/dspace/7022 · Cited by 49
Rapid Proliferation of Pandemic Research: Implications for Dual-Use Risks
Musunuri, S., Sandbrink, J. B., Monrad, J. T., Palmer, M. J., & Koblentz, G. D. (2021) · mBio · doi:10.1128/mbio.01864-21 · Cited by 39
Mamedov, T., Yuksel, D., Ilgın, M., Gürbüzaslan, İ., Gulec, B., MAMMADOVA, G., Özdarendeli, A., Yetişkin, H., Kaplan, B., Pavel, S. T. I., et al. (2021) · Vaccines · doi:10.3390/vaccines9111337 · Cited by 42
Neerukonda, S. N., Vassell, R. A., Lusvarghi, S., Wang, R., Echegaray, F., Bentley, L., Eakin, A. E., Erlandson, K. J., Katzelnick, L. C., Weiss, C. D., et al. (2021) · Viruses · doi:10.3390/v13122485 · Cited by 31
Hydrogen deuterium exchange and other mass spectrometry- based approaches for epitope mapping
Jethva, P. N., & Gross, M. L. (2023) · Frontiers in Analytical Science · doi:10.3389/frans.2023.1118749 · Cited by 40
Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro
Pucci, F., & Rooman, M. J. (2021) · Viruses · doi:10.3390/v13050935 · Cited by 35
Vaquero, S. T., de Campos‐Mata, L., Ramada, J. M., Díaz, P., Navarro‐Barriuso, J., Ribas‐Llauradó, C., Melero, N. R., Carolis, C., Cerutti, A., Gimeno, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737083 · Cited by 39
Guruprasad, K. (2022) · Current Research in Structural Biology · doi:10.1016/j.crstbi.2022.01.002 · Cited by 41
“A comprehensive map of the spike protein RBD escape mutants against the monoclonal antibodies; LY-CoV016 (etesevimab) (Starr et al., 2021a) and LY-CoV555 (bamlanivi-mab) along with a combination cocktail of the two antibodies have been reported (Starr et al., 2021b).”
Perchetti, G. A., Zhu, H., Mills, M. G., Shrestha, L., Wagner, C., Bakhash, S. M., Lin, M. J., Xie, H. J., Huang, M.-L. W., Mathias, P. C., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27155 · Cited by 33
Maeda, D. L. N. F., Tian, D., Yu, H., Dar, N., Rajasekaran, V., Meng, S., Mahsoub, H. M., Sooryanarain, H., Wang, B., Heffron, C. L., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025622118 · Cited by 36
Gorchakov, A. A., Kulemzin, S. V., Guselnikov, S. V., Baranov, K. O., Николаевна, Б. Т., Mechetina, L. V., Volkova, O. Y., Najakshin, A. M., Chikaev, N. A., Chikaev, A. N., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00340-8 · Cited by 33
Virus Infection and Systemic Inflammation: Lessons Learnt from COVID-19 and Beyond
Faist, A., Janowski, J., Kumar, S., Hinse, S., Çalışkan, D. M., Lange, J., Ludwig, S., & Brunotte, L. (2022) · Cells · doi:10.3390/cells11142198 · Cited by 32
Predicting the mutational drivers of future SARS-CoV-2 variants of concern
Maher, M. C., Bartha, I., Weaver, S., di Iulio, J., Ferri, E., Soriaga, L. B., Lempp, F. A., Hie, B., Bryson, B. D., Berger, B., et al. (2021) · DSpace@MIT (Massachusetts Institute of Technology) · doi:10.34944/dspace/6982 · Cited by 31
Protective non-neutralizing SARS-CoV-2 monoclonal antibodies
Izadi, A., & Nordenfelt, P. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.06.003 · Cited by 38
Nkosi, T., Chasara, C., Mbatha, A., Nsimbi, M., Papadopoulos, A. O., Nguni, T. L., Karim, F., Moosa, M. Y. S., Gazy, I., Jambo, K., et al. (2022) · eLife · doi:10.7554/elife.78374 · Cited by 35
Parzych, E. M., Du, J., Ali, A., Schultheis, K., Frase, D. M., Smith, T. R. F., Cui, J., Chokkalingam, N., Tursi, N. J., Andrade, V. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33309-6 · Cited by 33
Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies
Sheward, D. J., Pushparaj, P., Das, H., Greaney, A. J., Kim, C., Kim, S., Hanke, L., Hyllner, E., Dyrdak, R., Lee, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101577 · Cited by 33
“28 Specifically, we removed mutations with an ACE2 binding score (cid”
InfluentialSelf-citationLi, X., Zhang, L., Chen, S., Ji, W., Li, C., & Ren, L. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104971 · Cited by 31
1 H qNMR-Based Metabolomics Discrimination of Covid-19 Severity
Correia, B. S. B., Ferreira, V. G., Piagge, P. M. F. D., Almeida, M. B., Assunção, N. A., Raimundo, J. R. S., Fonseca, F. L. A., Carrilho, E., & Cardoso, D. R. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00977 · Cited by 29
Structural basis of Omicron neutralization by affinity-matured public antibodies
Sheward, D. J., Pushparaj, P., Das, H., Kim, C., Kim, S., Hanke, L., Dyrdak, R., McInerney, G., Albert, J., Murrell, B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.03.474825 · Cited by 30
Liu, H., Kaku, C. I., Song, G., Yuan, M., Andrabi, R., Burton, D. R., Walker, L. M., & Wilson, I. A. (2022) · Communications Biology · doi:10.1038/s42003-022-03700-6 · Cited by 32
Evolution of Antiviral Drug Resistance in SARS-CoV-2
Dinata, R., Baindara, P., & Mandal, S. M. (2025) · Viruses · doi:10.3390/v17050722 · Cited by 34
Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
Lee, E.-J., & Oh, J. E. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0075 · Cited by 30
A Tale of Three Recent Pandemics: Influenza, HIV and SARS-CoV-2
Miranda, M., Pingarilho, M., Pimentel, V., Torneri, A., Seabra, S. G., Libin, P., & Abecasis, A. B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.889643 · Cited by 38
López-Morales, J., Vanella, R., Appelt, E. A., Whillock, S., Paulk, A. M., Shusta, E. V., Hackel, B. J., Liu, C. C., & Nash, M. A. (2023) · Small Science · doi:10.1002/smsc.202300095 · Cited by 32
Functional and antigenic landscape of the Nipah virus receptor-binding protein
Larsen, B. B., McMahon, T. E., Brown, J. T., Wang, Z., Radford, C. E., Crowe, J. E., Veesler, D., & Bloom, J. D. (2025) · Cell · doi:10.1016/j.cell.2025.02.030 · Cited by 33
“56,57 Our work prospectively maps all single mutations that escape antibodies while also assessing the impact of those mutations on RBP function, thereby providing a way to assess the potential for resistance mutations to emerge.”
Self-citationKaku, Y., Kuwata, T., Zahid, H. M., Hashiguchi, T., Noda, T., Kuramoto, N., Biswas, S., Matsumoto, K., Shimizu, M., Kawanami, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109385 · Cited by 30
“Moreover, variants that mutate to escape from antibody neutralization, which occurs during chronic infection (Kemp et al., 2021; Starr et al., 2021), as well as selection by the prototypic SARS-CoV-2-based vaccine, are a major concern for the treatment and prevention of SARS-CoV-2.”
Antwi, C. O., Belle, M., Ntim, S., Wu, Y., Affum‐Osei, E., Aboagye, M. O., & Ren, J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19137916 · Cited by 26
Towards a post-pandemic future for global pathogen genome sequencing
Ladner, J. T., & Sahl, J. W. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002225 · Cited by 40
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27
Graham, C., Seow, J., Huettner, I., Khan, H., Kouphou, N., Acors, S., Winstone, H., Pickering, S., Galao, R. P., Lista, M. J., et al. (2021) · doi:10.1101/2021.02.03.429355 · Cited by 27
Analysis of SARS-CoV-2 genome evolutionary patterns
Gupta, S., Gupta, D., & Bhatnagar, S. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.02654-23 · Cited by 29
“Multiple mutations in the omicron variant S protein may also influence its interaction with ACE2, thereby leading to antibody escape (15, 16).”
BackgroundLiu, Z., Wu, H., Egland, K. A., Gilliland, T. C., Dunn, M. D., Luke, T. C., Sullivan, E. J., Klimstra, W. B., Bausch, C. L., & Whelan, S. P. J. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1940652 · Cited by 26
Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations
Wu, L., Peng, C., Yang, Y., Shi, Y., Zhou, L., Xu, Z., & Zhu, W. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab383 · Cited by 28
Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing
Rea, I. M., & Alexander, H. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101494 · Cited by 29
McKimm‐Breschkin, J. L., Hay, A. J., Cao, B., Cox, R. J., Dunning, J. W., Moen, A. C., Olson, D., Pizzorno, A., & Hayden, F. G. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105227 · Cited by 30
“Although mutations leading to escape to neutralization by each of these antibodies are at orthogonal sites on the RBD (Starr et al., 2021c), some of the VOCs have evolved mutations leading to escape, e.g. E484K in both Beta and Gamma lineages, L452R in Delta and K417N/T in Beta, Gamma and Delta.”
InfluentialOuyang, W. O., Tan, T. J. C., Lei, R., Song, G., Kieffer, C., Andrabi, R., Matreyek, K. A., & Wu, N. C. (2022) · Science Advances · doi:10.1126/sciadv.add7221 · Cited by 28
S glycoprotein diversity of the Omicron variantPreprint
Sarkar, R., Lo, M., Saha, R., Dutta, S., & Chawla‐Sarkar, M. (2021) · medRxiv · doi:10.1101/2021.12.04.21267284 · Cited by 29
Carr, C. R., Crawford, K. H. D., Murphy, M., Galloway, J., Haddox, H. K., Matsen, F. A., IV, Andersen, K. G., King, N. P., & Bloom, J. D. (2024) · Immunity · doi:10.1016/j.immuni.2024.06.013 · Cited by 34
Self-citationCatching SARS-CoV-2 by Sequence Hybridization: a Comparative Analysis
Rehn, A., Braun, P. R., Knüpfer, M., Wölfel, R., Antwerpen, M. H., & Walter, M. C. (2021) · mSystems · doi:10.1128/msystems.00392-21 · Cited by 27
Rapid test to assess the escape of SARS-CoV-2 variants of concern
Heggestad, J. T., Britton, R. J., Kinnamon, D., Wall, S. A., Joh, D. Y., Hucknall, A., Olson, L. B., Anderson, J. G., Mazur, A., Wolfe, C. R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abl7682 · Cited by 26
“Likewise, we could prospectively assess the impact of modifications at important residues on immunity, as others have done ( 46 , 47 ), to identify mutations of concern.”
Greaney, A. J., Eguia, R. T., Starr, T. N., Khan, K., Franko, N., Logue, J. K., Lord, S. M., Speake, C., Chu, H. Y., Sigal, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010592 · Cited by 29
Self-citationThe mechanisms of immune response and evasion by the main SARS-CoV-2 variants
Chen, Q., Zhang, J., Wang, P., & Zhang, Z. (2022) · iScience · doi:10.1016/j.isci.2022.105044 · Cited by 30
Computationally designed proteins mimic antibody immune evasion in viral evolution
Youssef, N., Gurev, S. F., Ghantous, F., Brock, K. P., Jaimes, J. A., Thadani, N. N., Dauphin, A., Sherman, A. C., Yurkovetskiy, L., Soto, D., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.04.015 · Cited by 36
Up State of the SARS-COV-2 Spike Homotrimer Favors an Increased Virulence for New Variants
Giron, C. C., Laaksonen, A., & da Silva, F. L. B. (2021) · Frontiers in Medical Technology · doi:10.3389/fmedt.2021.694347 · Cited by 28
A survey on computational methods in discovering protein inhibitors of SARS-CoV-2
Liu, Q., Wan, J., & Wang, G. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab416 · Cited by 26
“Until June 2021, multiple major variants of SARS-CoV-2 have dominated the world, e.g. Alpha virus (found in England), Beta virus (found in South Africa), Delta virus (found in India), [15].”
BackgroundAhamad, S., Ali, H., Secco, I., Giacca, M., & Gupta, D. K. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.866474 · Cited by 27
Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
Struble, E. B., Rawson, J. M. O., Stantchev, T. S., Scott, D., & Shapiro, M. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051538 · Cited by 29
Sathi, S. N., Umasankar, P. K., Sreekumar, E., Nair, R. R., Joseph, I., Nori, S. R. C., Philip, J. S., Prasad, R., Navyasree, K. V., Ramesh, S. T., et al. (2022) · BMC Molecular and Cell Biology · doi:10.1186/s12860-021-00403-4 · Cited by 29
Sokhansanj, B. A., Zhao, Z., & ROSEN, G. L. (2022) · Biology · doi:10.3390/biology11121786 · Cited by 31
Reading the repertoire: Progress in adaptive immune receptor analysis using machine learning
O’Donnell, T. J., Kanduri, C., Isacchini, G., Limenitakis, J. P., Brachman, R. A., Alvarez, R. A., Haff, I. H., Sandve, G. K., & Greiff, V. (2024) · Cell Systems · doi:10.1016/j.cels.2024.11.006 · Cited by 30
Metadata
- Authors
- Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D.
- Affiliations
- Fred Hutch Cancer Center (US)
- University of Washington (US)
- Brigham and Women's Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Bloom, Jesse D.
- ORCID
- Venue
- Science
- Published
- 2021-02-19
- Volume
- 371
- Issue
- 6531
- Pages
- 850-854
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963219
- OpenAlex
- W3125266951
- Cited by
- 743
- References
- 40
- Citations by year
- 2026: 31 · 2025: 37 · 2024: 56 · 2023: 104 · 2022: 232 · 2021: 279
- FWCI
- 53.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- Funders
- Howard Hughes Medical Institute (Investigator)
- National Institute of Allergy and Infectious Diseases (R01AI127893, R01AI141707)
- Bill and Melinda Gates Foundation (INV-004949)
- Damon Runyon Cancer Research Foundation (DRG-2381-19)
- Massachusetts Consortium for Pathogen Readiness
- Washington Research Foundation (Innovation Fellow)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, antibody escape, receptor binding domain, viral mutations, monoclonal antibodies, antibody binding, viral surveillance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.